About us
Tackling the toughest cancers.
Head on.

Penetration of anti-cancer agents into and throughout solid tumours is widely recognised as presenting a major limitation to their effectiveness.
SonoTran® is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
Our team.
Nicholas Adams
Chief Business OfficerDr Christian Coviello
Chief Technology Officer & Co-FounderDr. Marianna Lalla MD PhD MPH CCT (PharmMed., PeadSurg.)
Chief Medical OfficerDr Allison Jeynes MD, FFPM (UK)
Non-Executive ChairAndrew Mullen MBA
Chief Operating OfficerGene Saragnese
Non-Executive DirectorDavid Preston
Finance DirectorDr Cliff Rowe
Development DirectorGlyn Edwards MBE
Executive DirectorDr Matthew Frohn
Non-Executive DirectorGeorge Robinson
Board MemberProf. Constantin Coussios OBE FREng
Non-Executive Director & Co-FounderProf. Fergus Gleeson FRCP FRCR
Clinical AdvisorProf. Hardev Pandha MB ChB (Birm) FRACP FRCP PhD CSST (Medical Oncology)
Clinical AdvisorMr Robert Jones
Clinical AdvisorDr Colin Story
Co-FounderProf. Robert Carlisle
Co-FounderOur values.
Our story.
OxSonics was founded in 2013 to commercialise ground-breaking technological advances developed over more than ten years at the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) at the University of Oxford in the UK. BUBBL is an internationally-recognized centre of excellence in therapeutic ultrasound and drug delivery within the Oxford Institute of Biomedical Engineering.
Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran® Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.
Today, SonoTran® is being evaluated clinically and we’re working with multiple partners to tackle the toughest cancers, head on.
Our supporters. Our collaborators.
Longwall Ventures
Oxford Technology and Innovations EIS Fund

MMK Capital
Perivoli Innovations
University of Oxford
Wellcome
